¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦ 73Â÷ ´ëÇѺñ´¢ÀÇÇÐȸ Á¤±âÇмú´ëȸ (DAY3) : 2021-11-05

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Á¦ 73Â÷ ´ëÇѺñ´¢ÀÇÇÐȸ Á¤±âÇмú´ëȸ (DAY3) : 2021-11-05
±³À°ÀÏÀÚ : 2021-11-05
±³À°Àå¼Ò : ¼­¿ï COEX Grand Ballroom A(Room101+102+103)  
±³À°ÁÖÁ¦ : Á¦ 73Â÷ ´ëÇѺñ´¢ÀÇÇÐȸ Á¤±âÇмú´ëȸ (DAY3)
ÁÖÃÖ±â°ü : ´ëÇѺñ´¢ÀÇÇÐȸ(19.2 ¸íĪº¯°æ ´ëÇѺñ´¢±â°úÇÐȸ)
´ã´çÀÚ : ±èÁöÇü
¿¬¶ôó : 02-573-8190  
À̸ÞÀÏ : urology@urology.or.kr      
±³À°Á¾·ù : ºñ´¢ÀÇÇаú      
Âü¼®¿¹»óÀοø : 900¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 110,000¿ø      
ºñ°í ºÀÁ÷ȸ¿ø: 110,000¿ø/°³¿øȸ¿ø: 110,000¿ø/±ºÀÇ°ü,°øº¸ÀÇ: 66,000¿ø/Àü°øÀÇ: 66,000¿ø/Ÿ°úÀü¹®ÀÇ:120,000¿ø/Ÿ°úÀü¹®ÀÇ(1Àϵî·Ï):88,000¿ø/°£È£»ç: 66,000¿ø/°£È£»ç(1Àϵî·Ï):33,000¿ø/¿¬±¸¿ø:66,000¿ø/Á¦¾àȸ»ç ¹× ÀÇ·á±âȸ»ç: 120,000¿ø *»çÀüµî·Ï ±âÁØ      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 09:00~09:15 Daily highlight  ±è¼ºÇÑ(±¹¸³¾Ï¼¾Å¸) 
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 09:15~09:30 Active surveillance in low risk bladder cancer  Á¤½ÂÀÏ(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 09:30~09:45 Molecular biomarkers for response of neoadjuvant chemotherapy in MIBC  ÀåÀÎÈ£(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 09:45~10:00 Evoling landscape of management for metastatic hormone-sensitive prostate cancer (mHSPC)  Á¤À翵(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 10:00~10:15 Radiomics as a novel approach to improved characterization of small renal masses  È«¼ºÈÄ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 10:15~10:30 Comparative estimating the impact of PSA screening in Asia America-Europe  °í¿µÈÖ(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 10:30~10:45 Future perspectives of microbiomics and urolithiasis  ÀÌÁÖ¿ë(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 10:45~11:00 The effectiveness of percutaneous tibial nerve stimulation for overactive bladder syndrome  Ã߹μö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 11:00~11:15 Treatment strategy for bladder outlet obstruction in middle age  ½Åµ¿±æ(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 11:15~11:30 Anticholinergic burden in Adults with overactive bladder: Focus on multiple anticholinergic use  Á¶¿µ»ï(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 11:30~11:45 Impact of male circumcision on sexual function  ÀÌ¿ø±â(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 11-05 Grand Ballroom A(Room101+102+103) 11:45~12:00 UTI vaccine as an alternative to antibiotics  Á¤È«(°Ç±¹ÀÇ´ë) 
½Ä»ç 11-05  12:00~13:00 ½Ä»ç  () 
±³À°½Ã°£ 11-05 D (Room.203) 13:00~13:05 Apalutamide for Metastatic Castration-Sensitive Prostate Cancer: Outcomes in High-Volume and Low-Volume Disease From the TITAN Final Analysis  Á¤º´ÇÏ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-05 D (Room.203) 13:05~13:10 Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer treated by either early docetaxel or abiraterone acetate  ±èÁرÔ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-05 D (Room.203) 13:10~13:15 Outcomes of metastatic lymph node only hormone naive and castrate resistant prostate cancer treated with PSMA-Lutetium radioligand therapy  William Yaxley(QEII Jubilee Hospital Brisbane Australia) 
±³À°½Ã°£ 11-05 D (Room.203) 13:15~13:20 Initial experience of [177Lu]Ludotadipep treatment in patients with [18F]PSMA PET CT positive metastatic castration-resistant prostate cancer  ½Åµ¿È£(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-05 D (Room.203) 13:20~13:25 The value of [F-18]Florastamin Prostate Specific membranous antigen (PSMA) PET/CT at initial diagnosis of prostate cancer compared with multi-parametric magnetic resonance imaging (mpMRI)  ±ÇÇõÀç(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-05 D (Room.203) 13:25~13:30 Prediction of clinically significant prostate cancer using polygenic risk models in Asians  ¼Û»óÇå(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-05 D (Room.203) 13:30~13:35 Relapse Rates after LDR Brachytherapy for low and intermediate risk Prostate Cancer: 6-year median follow up at a tertiary referral centre  Athos Katelaris(Department of Urology St George Hospital Sydney Australia) 
±³À°½Ã°£ 11-05 D (Room.203) 13:35~13:40 Effect of the ultrasound characteristics of regions of interest by MRI and additional target biopsy around the borderline on the detection of prostate cancer in MRI/TRUS software fusion biopsy  ¼Û¿øÈÆ(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 11-05 D (Room.203) 13:40~13:45 Usefulness of grayscale values of hypoechoic lesions matched with target lesions observed on magnetic resonance imaging for the prediction of clinically significant prostate cancer  ±èµ¿±Õ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-05 D (Room.203) 13:45~13:50 Reliability of a combination of targeted and systematic prostate biopsies in patients with MRI-visible lesions: A comparison study between combined biopsies and prostatectomy specimens  ³ëÅÂÀÏ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 11-05 D (Room.203) 13:50~13:55 Weekly versus 2-weekly versus 3-weekly docetaxel to treat metastatic castration-resistant prostate cancer  °í¿ë¼®(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-05 D (Room.203) 13:55~14:00 Åä·Ð  () 
±³À°½Ã°£ 11-05 D (Room.203) 14:00~15:00 Robotic ureteroplasty with buccal mucosa graft  ÇÑ´öÇö(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-05 D (Room.203) 15:00~16:00 Excision and primary anastomosis for bulbar urethral stricture: Step-by-step technique  ±è¼ö¿õ(¼­¿ïÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦ 73Â÷ ´ëÇѺñ´¢ÀÇÇÐȸ Á¤±âÇмú´ëȸ (DAY3) : 2021-11-05""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѺñ°úÇÐȸ Á¦9ȸ Rhinology Open Forum : 2021-11-06
´ÙÀ½±Û ´ëÇÑ¿Ü°úÇÐȸ Annual Congress of KSS(Korean Surgical Society) 2021 (73Â÷ Çмú´ëȸ) 2ÀÏÂ÷ : 2021-11-05
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20895 ¼­¿ï ´ëÇѼҾƽÅÀåÇÐȸ (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 3 2024-05-28
20894 ´ëÀü Ãæ³²´ëÇб³º´¿ø 2024³â °³¿øÀÇ¿Í ÇÔ²²ÇÏ´Â ³»°ú ¿¬¼ö°­Á : 2024-06-30 0 3 2024-05-28
20893 ¼­¿ï ´ëÇѳúÁ¹ÁßÇÐȸ 6¿ù º¸¼ö±³À° : 2024-06-30 0 107 2024-05-27
20892 ¼­¿ï (¿Â¶óÀÎ)Á¦22Â÷ ¼­¿ïƯº°½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-30 0 9 2024-05-27
20891 °æ±â (¿Â¶óÀÎ)Á¦21Â÷ °æ±âµµÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2024-06-30 0 24 2024-05-27
20890 Àü³² 2024³â ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ ¿¬¼ö°­Á : 2024-06-30 0 10 2024-05-27
20889 Ãæ³² ´ëÇÑÁ¤Çü¿Ü°úÃÊÀ½ÆÄÇÐȸ - Á¦19Â÷ Ãá°èÇмú´ëȸ ¹× Á¦38Â÷ ±Ù°ñ°Ý°è ÃÊÀ½ÆÄ¿öÅ©¼¥ (Basic Course) : 2024-06-30 0 5 2024-05-27
20888 ºÎ»ê Á¦3ȸ ´ëÇÑÅõ¼®Çùȸ ºÎ»êÁöȸ ½ÉÆ÷Áö¾ö : 2024-06-29 0 4 2024-05-27
20887 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7ȸ A to Z (Atherosclerosis to Zero) ¿¬¼ö°­Á ÇÁ·Î±×·¥ : 2024-06-29 0 1 2024-05-27
20886 °æ±â 2024³âµµ ³²¾çÁÖ½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-29 0 1 2024-05-27
20885 ¼­¿ï (¿Â¶óÀÎ)Á¦14ȸ ´ëÇÑ°¨¿°ÇÐȸ Æò»ý±³À° ÇÁ·Î±×·¥ °¨¿°Áúȯ ÃÖ½ÅÁö°ß : 2024-06-29 0 6 2024-05-27
20884 ¼­¿ï Á¦24Â÷ ´ëÇѽÅÀåÇÐȸ ½ÅÀ̽Ŀ¬±¸È¸ ¿¬¼ö°­Á : 2024-06-29 0 1 2024-05-27
20883 ¼­¿ï 2024 ¼±Ãµ¼º Ⱦ°æ¸· Å»Àå ÄÚȣƮ (K-CDH) ±³À°¼¼¹Ì³ª : 2024-06-29 0 9 2024-05-27
20882 ¼­¿ï 2024 ¿©¼º½ÉÀåÁúȯ¿¬±¸È¸ ÇÏ°è ½ÉÆ÷Áö¾ö : 2024-06-29 0 1 2024-05-27
20881 °­¿ø 2024 ³âµµ Á¤Çü¿Ü°úÇб³½Ç °³¿øÀÇ¿¬¼ö°­Á : 2024-06-29 0 7 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷